GILD vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
Gilead Sciences and Regeneron are both major biotechnology companies with dominant franchises in their respective disease areas, but Gilead Sciences centers on HIV treatment and prevention, while Regeneron centers on immunology treatment for allergic and inflammatory conditions, both companies working to diversify their pipelines into oncology and other disease areas.
Gilead Sciences offers exposure to a durable, dominant HIV franchise with newer prevention therapies extending its growth runway, while Regeneron offers exposure to a leading immunology franchise backed by a proprietary antibody discovery platform. Consider whether you prefer Gilead's HIV franchise durability or Regeneron's immunology leadership and pipeline technology.
GILD holds the edge across 3 of 5 key metrics in this comparison. REGN leads on both 1-year return (+46.81%) and forward P/E quality (13.10x vs 14.73x for GILD), a relatively favorable combination of momentum and valuation. On fundamentals, REGN is growing revenue faster (16.70%), while GILD maintains the higher operating margin (33.68%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +8.05% for GILD and +5.82% for REGN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a dominant, durable HIV treatment and prevention franchise
- Believe newer HIV prevention therapies extend the growth runway beyond legacy products
- Value diversification progress into oncology beyond the core HIV business
- Prefer a company with an established, high-margin core revenue base
- Want exposure to a leading immunology therapy franchise for allergic and inflammatory conditions
- Believe a proprietary antibody discovery platform supports durable long-term pipeline productivity
- Value diversification into oncology and ophthalmology beyond the core immunology franchise
- Are comfortable with emerging competition risk to its leading immunology therapy
| Metric | GILD | REGN |
|---|---|---|
| AI scorei | 51.0 | 42.5 |
| AI ranki | #394 | #841 |
| Latest closei | $151.00 | $827.72 |
| 1M returni | +14.60% | +7.69% |
| 6M returni | +4.04% | +8.21% |
| 1Y returni | +33.64% | +46.81% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GILD | REGN |
|---|---|---|
| 1Y ago | $13.39K (+33.9%) started 2025-09-04 | $14.59K (+45.9%) started 2025-09-04 |
| 5Y ago | $28.9K (+189.0%) started 2021-09-07 | $12.43K (+24.3%) started 2021-09-07 |
| 10Y ago | $38.99K (+289.9%) started 2016-09-06 | $20.86K (+108.6%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | GILD | REGN |
|---|---|---|
| Market capi | $180.64B | $81.77B |
| Trailing P/Ei | 17.74 | 19.65 |
| Forward P/Ei | 14.73 | 13.10 |
| Price/Salesi | 4.87 | 3.78 |
| EV/Revenuei | 6.63 | 4.76 |
| Analyst targeti | $157.41 | $840.43 |
| Target upsidei | +8.05% | +5.82% |
| Metric | GILD | REGN |
|---|---|---|
| Revenue growthi | 10.20% | 16.70% |
| Earnings growthi | 54.80% | -4.50% |
| EPS growthi | +54.80% | -4.50% |
| FCF margini | +32.07% | +19.73% |
| Operating margini | 33.68% | 33.11% |
| Profit margini | -10.64% | 27.87% |
| ROIC proxyi | -20.68% | 14.04% |
| Return on equityi | -20.68% | 14.04% |
| Dividend yieldi | 2.20% | 0.47% |
| Betai | 0.34 | 0.19 |
| Debt/equityi | 223.47 | 8.54 |
| Current ratioi | 1.26 | 3.33 |
| Quick ratioi | 0.90 | 2.63 |
Over the past year, GILD and REGN have moved weakly in the same direction (correlation of 0.32), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GILD | REGN |
|---|---|---|---|
| 1Y | Growthi | +33.90% | +45.93% |
| CAGRi | +33.96% | +46.00% | |
| Volatilityi | 26.62% | 33.52% | |
| Sharpe ratioi | 1.06 | 1.16 | |
| Sortino ratioi | 1.68 | 1.82 | |
| Max drawdowni | 22.03% | 26.05% | |
| Current drawdowni | 3.08% | 2.85% | |
| Avg drawdowni | 8.02% | 7.98% | |
| Ulcer Indexi | 10.22% | 10.96% | |
| Max daily dropi | 3.72% | 9.82% | |
| Max wkly dropi | 5.98% | 12.87% | |
| 5Y | Growthi | +146.36% | +24.10% |
| CAGRi | +19.79% | +4.42% | |
| Volatilityi | 24.75% | 31.11% | |
| Sharpe ratioi | 0.67 | 0.15 | |
| Sortino ratioi | 1.04 | 0.21 | |
| Max drawdowni | 26.59% | 59.69% | |
| Current drawdowni | 3.08% | 30.93% | |
| Avg drawdowni | 8.96% | 20.10% | |
| Ulcer Indexi | 10.95% | 27.83% | |
| Max daily dropi | 10.15% | 19.01% | |
| Max wkly dropi | 9.78% | 20.21% | |
| 10Y | Growthi | +167.37% | +108.38% |
| CAGRi | +10.34% | +7.62% | |
| Volatilityi | 25.56% | 32.17% | |
| Sharpe ratioi | 0.34 | 0.25 | |
| Sortino ratioi | 0.50 | 0.36 | |
| Max drawdowni | 30.47% | 59.69% | |
| Current drawdowni | 3.08% | 30.93% | |
| Avg drawdowni | 13.24% | 21.22% | |
| Ulcer Indexi | 15.16% | 26.82% | |
| Max daily dropi | 10.15% | 19.01% | |
| Max wkly dropi | 12.29% | 20.21% |
| Category | GILD | REGN |
|---|---|---|
| Company | Gilead Sciences, Inc. | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | A biopharmaceutical company with a leading HIV treatment and prevention franchise, alongside a growing oncology portfolio, focused on maintaining its dominant position in HIV therapeutics while diversifying revenue into new disease areas. | A biotechnology company known for its immunology franchise centered on a leading injectable therapy for allergic and inflammatory conditions, alongside a growing oncology and ophthalmology pipeline built on internally developed antibody technology. |
| Investor focus | HIV franchise durability and growth from newer treatment and prevention therapies, oncology pipeline progress, and overall pipeline diversification beyond its core HIV business. | Growth of its leading immunology therapy amid emerging competition, oncology and ophthalmology pipeline progress, and productivity of its proprietary antibody discovery platform. |
- Dominant, long-standing position in HIV treatment and prevention provides a durable, high-margin core revenue base
- Newer HIV prevention therapies extend the franchise's growth runway beyond legacy treatment products
- Growing oncology portfolio provides diversification beyond its historically core HIV business
- Leading immunology therapy has driven substantial revenue growth and cash flow to fund pipeline expansion
- Proprietary antibody discovery technology platform supports an internally generated pipeline across multiple disease areas
- Diversification into oncology and ophthalmology provides growth avenues beyond its core immunology franchise
- Significant revenue concentration in its HIV franchise creates exposure if new treatment approaches or competitors emerge
- Oncology pipeline diversification efforts must succeed to meaningfully reduce dependence on the core HIV business
- Faces eventual patent expiration risk across its HIV product portfolio over the long term
- Significant revenue concentration in its leading immunology therapy creates exposure as new competitors enter the market
- Pipeline diversification into oncology and other areas must succeed to reduce dependence on its core franchise
- Biotechnology research and development requires sustained, significant capital investment with uncertain outcomes
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.